Evidence map›Paper›PMID 29843813›Full record

ArticleJournal of ovarian research2018

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.

Maureen L Drakes, Swati Mehrotra, Monica Aldulescu, Ronald K Potkul, Yueying Liu, Anne Grisoli, Cara Joyce, Timothy E O'Brien, M Sharon Stack, Patrick J Stiff

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube.American journal of reproductive immunology (New York, N.Y. : 1989) · 2023
    Article
  16. Article
  17. Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maureen L DrakesCardinal Bernardin Cancer Center, Oncology Research Institute, Department of Medicine, Loyola University Chicago, Bldg. 112, Room 232, 2160 South First Avenue, Maywood, IL, 60153, USA. mdrakes@luc.edu.
Swati MehrotraDepartment of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Monica AldulescuDepartment of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Ronald K PotkulDepartment of Obstetrics and Gynecology, Loyola University Chicago, Maywood, IL, USA.
Yueying LiuDepartment of Chemistry & Biochemistry, Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Anne GrisoliDepartment of Chemistry & Biochemistry, Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Cara JoyceDepartment of Public Health Sciences, Loyola University Chicago, Maywood, IL, USA.
Timothy E O'BrienDepartment of Mathematics & Statistics, and Institute of Environmental Sustainability, Loyola University Chicago, Chicago, IL, USA.
M Sharon StackDepartment of Chemistry & Biochemistry, Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Patrick J StiffCardinal Bernardin Cancer Center, Oncology Research Institute, Department of Medicine, Loyola University Chicago, Bldg. 112, Room 232, 2160 South First Avenue, Maywood, IL, 60153, USA.
Loyola University Chicago · USUniversity of Notre Dame · USCancer Research Institute · US

Funding

Receptor Cross-Talk in Early Metastatic DisseminationR01CA109545 · NCI · UNIVERSITY OF NOTRE DAME · PI STACK, MARY SHARON · 2006 to 2022
$4.3M
Cardinal Bernardin Cancer Center/ Harper Cancer Research Institute N/ANCI NIH HHS R01 CA109545Perritt Charitable Foundation N/A
6 · The paper itself

Abstract

backgroundOvarian cancer is the major cause of death among gynecologic cancers with 75% of patients diagnosed with advanced disease, and only 20% of these patients having a survival duration of five years. Treatments blocking immune checkpoint molecules, programmed cell death (PD-1) or its ligand PD-ligand- I (PD-L1) have produced a beneficial and prolonged effect in a subgroup of these patients. However, there is debate in the literature concerning the prognostic value of the expression of these molecules in tumors, with immunotherapy responsiveness, and survival. We evaluated the immune landscape of the ovarian tumor microenvironment of patients, by measuring the impact of the expression of tumor PD-1, PD-L1 and infiltrating lymphocytes on stage and grade of tumors and survival, in a cohort of 55 patients with gynecologic malignancies. Most patients under study were diagnosed with advanced disease ovarian cancer.

resultsOur studies revealed that a low density of PD-1 and of PD-L1 expressing cells in tumor tissue were significantly associated with advanced disease (P = 0.028 and P = 0.033, respectively). Moreover, PD-L1 was expressed significantly more often in high grade tumors (41.5%) than in low grade tumors of patients (7.7%) (P = 0.040). The presence of CD3 or of FoxP3 infiltrating cells with PD-L1 in patient tumors did not impact the significance of the association of PD-L1 with high grade tumors (P = 0.040), and our analyses did not show an association between the presence of PD-1 or PD-L1 and survival.

conclusionsWe conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling.

Indexed as

PrognosisAgedB7-H1 AntigenCD3 ComplexDisease-Free SurvivalFemaleForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansImmunotherapyKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm StagingOvarian NeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanCD3 ComplexForkhead Transcription FactorsFOXP3 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCancer immunotherapyHigh grade diseaseOvarian cancerProgrammed cell death-1Programmed cell death-1 ligand

Identifiers

PMID29843813
PMCPMC5975524
OpenAlexW2807005867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.